Abbott Labs Stock Price, News & Analysis

Abbott (NYSE:ABT) has scheduled its second-quarter 2025 financial results announcement for Thursday, July 17, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. An archived version of the call will be made available later the same day.

A clinical trial of Abbott's (ABT) Healthy Food Rx program, presented at ADA's 85th Scientific Sessions, demonstrated significant benefits for diabetes patients. The study of 364 participants over six months showed improved diet quality with increased vegetable consumption (0.37 vs 0.03 servings/day) and fruit intake. Physical health status improved markedly in program participants (38% to 63%) compared to the control group (47% to 50%). Both groups saw significant A1C level improvements, decreasing by 0.7% in the intervention group and 1.2% in the control group. The program, launched in 2021, has reached over 1,700 participants in Stockton, California, where 60% of the population has diabetes or pre-diabetes. Participant satisfaction was notably high, with 98% satisfied and 97% utilizing most or all provided food.

Abbott (NYSE: ABT) has announced its 406th consecutive quarterly dividend of $0.59 per share, demonstrating a remarkable track record of consistent shareholder returns since 1924. The dividend will be paid on August 15, 2025, to shareholders of record as of July 15, 2025. The company has achieved an impressive milestone of increasing its dividend payout for 53 consecutive years, securing its position in the prestigious S&P 500 Dividend Aristocrats Index, which recognizes companies with at least 25 years of consecutive dividend increases.

Abbott (ABT) has received FDA approval for its Tendyne™ transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device that replaces malfunctioning mitral valves without open-heart surgery. The system is specifically designed for patients with severe mitral annular calcification (MAC) who are high-risk candidates for traditional surgery.

The innovative Tendyne system features a self-expanding valve that is delivered through a small chest incision and is fully repositionable during implantation. The device is available in multiple sizes to accommodate different patient anatomies and offers a new treatment option for patients who cannot undergo open-heart surgery or mitral repair with Abbott's MitraClip™ device.

Abbott's FreeStyle Libre® continuous glucose monitoring (CGM) technology has demonstrated groundbreaking results in reducing cardiovascular disease-related hospitalizations for diabetes patients. The REFLECT real-world studies show a 78% reduction in heart-related hospitalizations for Type 1 diabetes patients with prior severe low blood sugar episodes. For Type 1 diabetes patients with no prior cardiovascular disease history, hospitalizations decreased by 80%, while those with prior history saw a 49% reduction. The technology also showed similar benefits for Type 2 diabetes patients on insulin. This is particularly significant as diabetes affects approximately 589 million people globally, with diabetic patients being 2-4 times more likely to develop heart disease than non-diabetics. The findings suggest that Libre technology could lead to lower healthcare costs through reduced hospital admissions while helping patients better manage both their diabetes and cardiovascular health.

Cadrenal Therapeutics (NASDAQ: CVKD) reported its Q1 2025 financial results and corporate updates. Key highlights include: appointment of Dr. James Ferguson as Chief Medical Officer, a successful FDA Type D Meeting providing guidance for tecarfarin's Phase 3 trial, and a Collaboration Agreement with Abbott for the TECH-LVAD trial. The company completed technical transfer of tecarfarin manufacturing to a U.S. CDMO and conducted market research showing growth potential in the LVAD market. Financial results show R&D expenses of $1.7M (up from $0.6M in Q1 2024), G&A expenses of $2.3M (up from $1.1M), and a net loss of $3.8M. Cash position stands at $7.3M as of March 31, 2025, down from $10.0M at year-end 2024.

Abbott (ABT) and Real Madrid announced the creation of the 'Abbott Dream Team' program, seeking talented soccer players aged 18-19 across the U.S. The program will host tryouts in five major cities (Chicago, Dallas, Los Angeles, Philadelphia, and Washington, D.C.) from June 17 to July 24, 2025, with each location accepting up to 250 participants. Eleven selected players will travel to Madrid to train at Real Madrid's facilities and receive instruction from their coaches. American soccer legend Clint Dempsey will mentor the athletes. The program, part of the 'Beat Malnutrition' campaign, includes health and nutrition education from Abbott experts. Since 2022, the Abbott-Real Madrid partnership has provided over 67,000 hours of health education and screened 6,800 children for malnutrition risk in 12 countries.

MotoAmerica has become the first professional sports organization globally to implement Abbott's (NYSE: ABT) innovative blood test for concussion evaluation at race events. The i-STAT TBI test, which received FDA clearance in 2024, uses Abbott's portable i-STAT® Alinity® device to analyze whole blood samples and deliver results in just 15 minutes. The test measures two brain-specific biomarkers (UCH-L1 and GFAP) to help determine if a CT scan is needed following a suspected mild traumatic brain injury. This groundbreaking technology will be available at all MotoAmerica races in 2025, starting with the Michelin Raceway Road event in Atlanta (May 2-4). The test requires only a few drops of blood and provides objective data to assist healthcare professionals in making quick, informed decisions about rider safety and treatment needs.

Abbott has partnered with Epic to integrate data from its FreeStyle Libre continuous glucose monitoring (CGM) systems directly into Epic's electronic health record systems in the U.S. This first-of-its-kind integration allows data from users' LibreView accounts to automatically link to Epic's platform.

Through Epic's Aura software, over 575,000 U.S. healthcare providers serving 280 million patients will gain streamlined access to patients' glucose data within their existing workflows. The collaboration aims to enhance care efficiency by enabling providers to view glucose data before, during, and after patient consultations.

Key benefits include:

• Improved workflow efficiency for healthcare providers
• Seamless access to CGM data in patient charts
• Enhanced patient-provider collaboration
• More time for care management versus administrative tasks

Abbott plans to expand this model to other medical devices and connected care platforms in the future. Healthcare providers interested in updates can contact Abbott at Libre.Epic@abbott.com.